{"title":"白细胞介素-1 抑制剂治疗复发性心包炎患者的有效性和安全性：随机对照试验的系统回顾和元分析》。","authors":"Yong Wan, Shuai He, Shasha Wang, Tingli Xu, Minfang Qi, Pengcheng Gan","doi":"10.1007/s40256-024-00653-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The efficacy and safety of interleukin-1 (IL-1) inhibitors in patients with recurrent pericarditis (RP) remain to be determined.</p><h3>Objective</h3><p>We aimed to conduct a meta-analysis to investigate the impact of IL-1 inhibitors on patients suffering from RP.</p><h3>Methods</h3><p>The Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases were systematically searched to identify articles investigating the effects of IL-1 inhibitors in patients with RP up until January 2024. Relevant data on study characteristics and results were selected based on predefined criteria. The results were combined using a random effects model.</p><h3>Results</h3><p>The study included a total of 102 patients from three open-label randomized controlled trials. Overall, the use of IL-1 inhibitors, in comparison to placebo, demonstrated a significant reduction in the risk of pericarditis recurrence [risk ratio (RR) 0.13; 95% confident interval (CI) 0.05–0.30; <i>p</i> < 0.05; <i>I</i><sup><i>2</i></sup> = 0%]. However, the administration of IL-1 inhibitors may lead to certain adverse events (AEs), including infections and injection-site reactions. The risk of AEs is significantly higher with IL-1 inhibitors compared with placebo (RR 1.88; 95% CI 1.30–2.72; <i>p</i> < 0.05; <i>I</i><sup><i>2</i></sup> = 0%). Nevertheless, the occurrence of serious AEs among patients was relatively rare, and no fatalities were reported.</p><h3>Conclusion</h3><p>This meta-analysis showed that IL-1 inhibitors can effectively reduce the risk of recurrence in patients with RP and are relatively safe.</p><h3>Registration</h3><p>PROSPERO identifier number CRD42023492904.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 4","pages":"537 - 545"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Interleukin-1 Inhibitors in the Management of Patients with Recurrent Pericarditis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\",\"authors\":\"Yong Wan, Shuai He, Shasha Wang, Tingli Xu, Minfang Qi, Pengcheng Gan\",\"doi\":\"10.1007/s40256-024-00653-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The efficacy and safety of interleukin-1 (IL-1) inhibitors in patients with recurrent pericarditis (RP) remain to be determined.</p><h3>Objective</h3><p>We aimed to conduct a meta-analysis to investigate the impact of IL-1 inhibitors on patients suffering from RP.</p><h3>Methods</h3><p>The Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases were systematically searched to identify articles investigating the effects of IL-1 inhibitors in patients with RP up until January 2024. Relevant data on study characteristics and results were selected based on predefined criteria. The results were combined using a random effects model.</p><h3>Results</h3><p>The study included a total of 102 patients from three open-label randomized controlled trials. Overall, the use of IL-1 inhibitors, in comparison to placebo, demonstrated a significant reduction in the risk of pericarditis recurrence [risk ratio (RR) 0.13; 95% confident interval (CI) 0.05–0.30; <i>p</i> < 0.05; <i>I</i><sup><i>2</i></sup> = 0%]. However, the administration of IL-1 inhibitors may lead to certain adverse events (AEs), including infections and injection-site reactions. The risk of AEs is significantly higher with IL-1 inhibitors compared with placebo (RR 1.88; 95% CI 1.30–2.72; <i>p</i> < 0.05; <i>I</i><sup><i>2</i></sup> = 0%). Nevertheless, the occurrence of serious AEs among patients was relatively rare, and no fatalities were reported.</p><h3>Conclusion</h3><p>This meta-analysis showed that IL-1 inhibitors can effectively reduce the risk of recurrence in patients with RP and are relatively safe.</p><h3>Registration</h3><p>PROSPERO identifier number CRD42023492904.</p></div>\",\"PeriodicalId\":7652,\"journal\":{\"name\":\"American Journal of Cardiovascular Drugs\",\"volume\":\"24 4\",\"pages\":\"537 - 545\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Cardiovascular Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40256-024-00653-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiovascular Drugs","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40256-024-00653-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景：白细胞介素-1（IL-1）抑制剂对复发性心包炎（RP）患者的疗效和安全性仍有待确定：我们旨在进行一项荟萃分析，研究 IL-1 抑制剂对复发性心包炎患者的影响：系统检索了 Cochrane Library、PubMed、EMBASE、ClinicalTrials.gov 和 Web of Science 数据库，以确定截至 2024 年 1 月研究 IL-1 抑制剂对 RP 患者影响的文章。研究特征和结果的相关数据根据预定义标准进行筛选。研究结果采用随机效应模型进行合并：研究共纳入了来自三项开放标签随机对照试验的102名患者。总体而言，与安慰剂相比，使用IL-1抑制剂可显著降低心包炎复发风险[风险比（RR）0.13；95% 置信区间（CI）0.05-0.30；P < 0.05；I2 = 0%]。然而，服用IL-1抑制剂可能会导致某些不良事件（AE），包括感染和注射部位反应。与安慰剂相比，IL-1抑制剂的不良反应风险明显更高（RR 1.88；95% CI 1.30-2.72；P < 0.05；I2 = 0%）。尽管如此，患者中发生严重AEs的情况相对较少，也没有死亡报告：这项荟萃分析表明，IL-1抑制剂能有效降低RP患者的复发风险，而且相对安全：PROSPERO标识符号：CRD42023492904。
Efficacy and Safety of Interleukin-1 Inhibitors in the Management of Patients with Recurrent Pericarditis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background
The efficacy and safety of interleukin-1 (IL-1) inhibitors in patients with recurrent pericarditis (RP) remain to be determined.
Objective
We aimed to conduct a meta-analysis to investigate the impact of IL-1 inhibitors on patients suffering from RP.
Methods
The Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases were systematically searched to identify articles investigating the effects of IL-1 inhibitors in patients with RP up until January 2024. Relevant data on study characteristics and results were selected based on predefined criteria. The results were combined using a random effects model.
Results
The study included a total of 102 patients from three open-label randomized controlled trials. Overall, the use of IL-1 inhibitors, in comparison to placebo, demonstrated a significant reduction in the risk of pericarditis recurrence [risk ratio (RR) 0.13; 95% confident interval (CI) 0.05–0.30; p < 0.05; I2 = 0%]. However, the administration of IL-1 inhibitors may lead to certain adverse events (AEs), including infections and injection-site reactions. The risk of AEs is significantly higher with IL-1 inhibitors compared with placebo (RR 1.88; 95% CI 1.30–2.72; p < 0.05; I2 = 0%). Nevertheless, the occurrence of serious AEs among patients was relatively rare, and no fatalities were reported.
Conclusion
This meta-analysis showed that IL-1 inhibitors can effectively reduce the risk of recurrence in patients with RP and are relatively safe.
期刊介绍：
Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.
Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.
The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
